Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update

Xenetic Biosciences Inc (NASDAQ:XBIO) was the recipient of a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 6,500 shares, a decline of 15.6% from the January 31st total of 7,700 shares. Approximately 0.5% of the company’s shares are short sold. Based on an average trading volume of 12,400 shares, the short-interest ratio is presently 0.5 days.

Hedge Funds Weigh In On Xenetic Biosciences

An institutional investor recently raised its position in Xenetic Biosciences stock. Renaissance Technologies LLC increased its stake in Xenetic Biosciences Inc (NASDAQ:XBIO) by 61.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,550 shares of the company’s stock after purchasing an additional 9,700 shares during the quarter. Renaissance Technologies LLC owned about 1.66% of Xenetic Biosciences worth $102,000 at the end of the most recent quarter. Institutional investors and hedge funds own 15.12% of the company’s stock.

Xenetic Biosciences Trading Down 1.8 %

XBIO opened at $3.99 on Wednesday. Xenetic Biosciences has a twelve month low of $2.78 and a twelve month high of $5.20. The firm has a market cap of $6.14 million, a price-to-earnings ratio of -1.50 and a beta of 2.17. The company has a fifty day simple moving average of $4.11 and a 200 day simple moving average of $4.03.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “neutral” rating on shares of Xenetic Biosciences in a report on Thursday, December 5th.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.